Cover Image

Obi, Naoko; Fukuda, Tsuguo; Nakayama, Noboru; Ervin, John F.; Bando, Yoshio; Nishimura, Toshihide; Nagatoishi, Satoru; Tsumoto, Kouhei; Kawamura, Takeshi

doi:10.1002/rcm.8118

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The eluted samples were separated by nanoflow reverse-phase LC followed by analysis using a Orbi-Fusion mass spectrometer (Thermo Fisher Scientific, San Jose, CA) equipped with a Dream spray nano-electrospray ionization source (Dream spray, AMR Inc., Tokyo, Japan) [9][10][11][12][13][14]. The LC used was an Advance UHPLC (ultra-high-performance liquid chromatography) instrument (Bruker-Daltonics, Bremen, Germany) equipped with a HTS PAL auto-sampler (CTC Analytics AG, Zwingen, Switzerland).…”

Section: Lc-ms Conditionsmentioning

confidence: 99%

Deep proteome analysis of time-series human plasma samples applied to Covid-19 antibody test

Fukuda,

Nakayama,

Chikaoka

et al. 2023

Preprint

View full text Add to dashboard Cite

For the purpose of Covid-19 antibody testing, the human plasma samples acquired over a period of 310 days from August 18, 2021, to June 22, 2022, were subjected to DIA LC-MS proteome analysis. This process led to the acquisition of a quantitative protein profile and allowed for the validation of the temporal behavior of expressed proteins within the samples. A total of 1502 proteins were identified from the plasma samples. Before vaccination, after the first dose, after the second dose, and during the period after contracting the novel coronavirus, protein quantification values during each event interval were compared. Despite minimal changes observed before and after Covid-19 vaccination, notable proteins exhibiting distinct high-expression and low-expression patterns were identified after contracting the novel coronavirus infection.

show abstract